A Combination of PKC412 and 5-azacytidine for the Treatment of Patients with Refractory, Relapsed or Untreated Acute Leukemia and Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.
Disease Group: Leukemia
Treatment Agent: 5-Azacytidine
Treatment Location: Only at MD Anderson
Sponsor: Celgene Corporation
Primary Objectives 1. To determine the clinical activity of the combination of 5-azacytidine and PKC412 in patients with refractory or relapsed acute leukemias and MDS. 2. To determine the toxicity profile of the combination of 5-azacytidine and PKC412 in patients with refractory or relapsed acute leukemias and MDS. Secondary Objectives 1. To determine induction of hypomethylation, DNA damage and FLT3 signaling during therapy with this combination and its correlation with response.
IRB Review and Approval Date: 03/02/2011
Recruitment Status: Not Accepting
Projected Accrual: N/A
1) Patients with MDS, CMML, AML or biphenotypic or bilineage leukemia
who have failed prior therapy. Patients with MDS or CMML should have
failed prior therapy with a hypomethylating agent and/or with
lenalidomide. Patients with AML should have failed any prior induction
therapy or have relapsed after prior therapy, or be previously untreated
and unable or unwilling to receive conventional chemotherapy (e.g.,
patients age >/=65 years). Patients with MDS or CMML who received
therapy with a hypomethylating agent and progress to AML are eligible at
the time of diagnosis of AML regardless any prior therapy for AML. The
WHO classification will be used for AML. Patients with MDS, CMML or AML
who have received no prior therapy are eligible if not candidates to
receive or refuse standard therapy.
2) Patients must have evidence of FLT3 activating mutations.
3) Age >/= 18 years
4) ECOG Performance Status </= 2
5) Adequate liver (bilirubin </= 2x ULN, ALT </= 2.5x ULN) and renal (creatinine </= 2x ULN) function
6) Patients must provide written informed consent.
7) Patients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.
8) Women of childbearing potential must practice contraception. Women considered not of childbearing potential include any of the following: no menses for at least 5 years or menses within 5 years but amenorrheic for at least 2 months and luteinizing hormone (LH) and follicular stimulating hormone (FSH) values within normal range (according to definition of postmenopausal for laboratory used) or bilateral oophorectomy or radiation castration and amenorrheic for at least 3 months. Females of childbearing potential: Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation.
9) **continued from above: Male patients with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study.
10) Sexually active males should use a condom during intercourse while taking drug and for 3 months after stopping midostaurin medication. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid .
11) Negative urine or serum pregnancy test within 2 weeks.
1) Patients with known allergy or hypersensitivity to PKC412, mannitol
or 5-azacytidine, or any of their components.
2) Patients who have received any treatment of midostaurin prior to study entry.
3) Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PKC412.
4) Patients who demonstrated primary resistance to any FLT3 inhibitor or who relapsed while on therapy with a FLT3 inhibitor.
5) Patients with any other known disease (except carcinoma in-situ) concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes with fasting glucose > 200 mg/dl despite optimal management, cardiovascular disease including congestive heart failure (NYHA Class III or IV), myocardial infarction within 6 months and poorly controlled hypertension with systolic > 160 mmHg and diastolic > 100 mmHg, chronic renal disease, or active uncontrolled systemic infection) which could compromise participation in the study.
6) Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis. HIV patients not on specific antiretroviral therapy are eligible for participation.
7) Patients who have had any major surgical procedure within 14 days of Day 1.
8) Patients unwilling or unable to comply with the protocol.
9) Patients with known advanced malignant disease of the central nervous system.
10) Impaired cardiac function including any of the following: Screening ECG with a QTc > 470 msec; Patients with congenital long QT syndrome; History or presence of sustained ventricular tachycardia; Any history of ventricular fibrillation or torsades de pointes; Bradycardia defined as HR < 50 bpm; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina < 6 months prior to starting study drug; CHF NY Heart Association class III or IV; Patients with an ejection fraction < 50% assessed by MUGA or ECHO scan within 14 days of Day 1.